Low Molecular Weight Heparin Market to Surpass US$ 6,539.3 Mn by 2030

Global Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), by End User (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,903.1 Million in 2022 and is expected to exhibit a CAGR of 6.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Major Key players in the market are collaborating with hospitals to strengthen their product portfolio. For instance, in January 2019, Bayer, Pharmaceutics company based in German in collaboration with Assistance Publique - Hopitaux de Paris is studying combination of rivaroxaban and low molecular weight heparin for neoplasm and venous thromboembolism, which is in phase 3. Both of these pipeline drugs are expected to complete their final stages of study during the forecast period, which in turn is expected to drive growth of the low molecular weight heparin market.

Global Low Molecular Weight Heparin Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the global low molecular weight heparin market, owing to increase in demand for low molecular weight heparin used in the treatment associated with COVID-19. For instance, in September 2020, according to the data published in National Center for Biotechnology Information, on March 11, 2020, the World Health Organization declared its assessment of coronavirus disease 2019 (COVID-19) as a global pandemic. The clinical records and laboratory indicators were extracted from electronic medical records of 42 patients with COVID-19 (21 of whom were treated with Low Molecular Weight Heparin, and 21 without Low Molecular Weight Heparin) hospitalized (Union Hospital of Huazhong University of Science and Technology) from February 1 to March 15, 2020. Changes in the percentage of lymphocytes before and after Low Molecular Weight Heparin treatment were significantly different from those in the control group (P = 0.011). Likewise, changes in the levels of D-dimer and fibrinogen degradation products in the Low Molecular Weight Heparin group before and after treatment were significantly different from those in the control group (P = 0.035). Remarkably, IL-6 levels were significantly reduced after Low Molecular Weight Heparin treatment (P = 0.006), indicating that, besides other beneficial properties, Low Molecular Weight Heparin may exert an anti-inflammatory effect and attenuate in part the ‘cytokine storm’ induced by the virus. Union Hospital of Huazhong University of Science and Technology results support the use of Low Molecular Weight Heparin as a potential therapeutic drug for the treatment of COVID-19, paving the way for a subsequent well-controlled clinical study.

Evidence has shown that COVID-19 infections can lead to an increased risk of blood clots. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death. Enoxaparin is a blood-thinning drug which has been used by doctors and nurses in hospitals for many years to prevent the thickening of blood which may lead to a clot. It is easier for doctors to prevent new blood clots from forming than treating existing blood clots. Half the patients in the study will receive the blood-thinning drug enoxaparin for three weeks, and half will receive no treatment. Individuals will be randomly allocated to one of these groups. After 21 days, the number of patients in each group who were either admitted to hospital, or died, will be compared. The number of patients in each group who developed a blood clot (venous thromboembolism) .Further comparisons will be made at both 50 and 90 days after the beginning of the study.

Global Low Molecular Weight Heparin Market: Key Developments

In August 2021, Bioiberica, Life Science Company, had taken initiation in production of the heparin with high therapeutic index. Heparin has been deemed an essential medicine by the World Health Organization (WHO) and, in fact, both unfractionated heparin (UFH) and its low molecular weight derivatives (LMWH) are the most widely used group of anticoagulants for the prevention and treatment of thrombosis worldwide. Currently, one out of every five doses of heparin administered in the world is produced by Bioibérica.

In May 2022, according to the data published by the National Center for Biotechnology Information, international clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term treatment of cancer-associated thrombosis (CAT). Several new randomized controlled trials (RCTs) have recently reported additional results on the safety and efficacy of DOACs in this setting. The study performed an updated meta-analysis of all publicly available data from RCTs comparing direct oral anticoagulants (DOACs) with low-molecular-weight heparins (LMWHs) for the treatment of cancer-associated thrombosis.

Browse 44 Market Data Tables and 39 Figures spread through 218 Pages and in-depth TOC on “Global Low Molecular Weight Heparin Market”-  Forecast to 2030, Global Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Atrial Fibrillation), by End User (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/low-molecular-weight-heparin-market-1491

Moreover, increasing organic and inorganic growth strategies employed by key players in the market is expected to drive adoption of Low Molecular Weight Heparin over the forecast period. For instance, in July 2018, Pfizer Inc., pharmaceutical and Biotechnology Corporation announced plans to invest US$ 465 million to establish a technically advanced sterile injectable pharmaceutical production facility at Michigan, U.S. The establishment of this advance manufacturing facility is expected to strengthen the company’s sterile injectable manufacturing capability.

Key Takeaways of the Global Low Molecular Weight Heparin Market:

• The global low molecular weight heparin markets expected to exhibit a CAGR of 6.7% during the forecast period due to the increasing adoption of inorganic strategies such as agreements by the key players in the market for developing irritable bowel syndrome drugs. For instance, in April 2018, Laboratorios Farmaceúticos Rovi SA, pharmaceutical company announced that it has signed a license expanding agreement with Hikma Pharmaceuticals PLC, Biopharmaceutical Company for ROVI’s enoxaparin biosimilar because of Hikma’s strong presence in Middle East and North Africa (MENA) region.
• Among drugs, the enoxaparin segment accounted for major market share in 2022. Enoxaparin (Lovenox) is EU approved low molecular weight heparin (LMWH) indicated to be used in various indications including prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness, inpatient treatment of acute DVT with or without pulmonary embolism, outpatient treatment of acute DVT without pulmonary embolism, prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI), among other indications.
• Among end use, hospitals segment held major market share in 2022. Low-molecular Weight Heparin (LMWH) is increasingly being used in emergency department and during surgery procedures in the hospitals as compared to Unfractioned Heparin (UFH), owing to increasing medical infrastructure along with surgical procedures.
• Major players operating in the global low molecular weight heparin market include Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.